Skip to main content
Premium Trial:

Request an Annual Quote

Orchid BioSciences Pockets $20M in Stock Offering

NEW YORK, Feb. 27 - Orchid BioSciences on Wednesday said it has pocketed approximately $20 million in a special stock offering announced last week.

Orchid said it sold 8 million shares of common stock that were offered through a prospectus supplement  in-line with the company's shelf-registration.

Robertson Stephens acted as the underwriter of the offering, and Orchid has granted the financial firm the option to buy as many as 1.2 million more. If taken, this option would dump $3 million more into Orchid's pot.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.